On June 22, Novo Nordisk rose 3.26% in pre-market trading, trading at approximately $44.45/share, with turnover of $994,800.

On the news front, Novo Nordisk CEO Mike Doustdar made his first visit to China since taking the helm, releasing a series of bullish announcements. The company plans to submit clinical data for oral Wegovy to Chinese regulators within months seeking marketing approval, while simultaneously committing an additional 200 million RMB investment to expand 1.5mL pre-filled injection pen assembly capacity at its Tianjin strategic production base. Doustdar also indicated that Novo Nordisk will increase BD transactions in China and is in active dialogue with multiple Chinese companies to supplement its pipeline.

On the international front, oral Wegovy recently received approval from UK regulators, becoming the first approved market in Europe, with clinical data demonstrating an average weight reduction of 13.6% over 64 weeks. The China filing combined with overseas expansion reinforces the company's global commercialization outlook in the GLP-1 space. Notably, while the semaglutide patent expired in China in March, regulatory data protection under the China-Switzerland Free Trade Agreement extends through early next year, providing continued market exclusivity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)